Addex Therapeutics Ltd. ADXN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Addex Therapeutics Ltd. (ADXN) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $35743 and net income of -$8M, a net margin of -22923.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -123%.
About Addex Therapeutics
Addex Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $512323 in 2017 to $35743 in 2025, a decline of about 28.3% a year. It was profitable in 1 of the last 9 years in our data. Its share count fell by 47% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35743 | $35743 | — | $2M | $2M | $3M | $4M | $3M | $7M | $512323 |
| Net income | -$8M | -$8M | $8M | -$13M | -$23M | -$17M | -$15M | -$15M | -$2M | -$3M |
| Free cash flow | -$3M | -$3M | -$6M | -$10M | -$18M | -$16M | -$14M | -$10M | $2M | -$2M |
| EPS (diluted) | $-7.56 | $-4.48 | $2.29 | $-3.70 | $-6.61 | $-4.94 | $-4.29 | $-4.49 | $-0.49 | $-0.99 |
| Net margin | -22923.5% | -22448.4% | — | -654.5% | -1462.6% | -486.9% | -331.5% | -521.6% | -24.5% | -656.2% |
| ROIC | — | — | -28.5% | -195.8% | -214.6% | -91.6% | -83.8% | -57.2% | -3.6% | -190.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Addex Therapeutics pay a dividend?
Not currently.
Is Addex Therapeutics a good stock to buy?
We do not give buy or sell advice. Addex Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.